Granulosa Cell Tumour of the Ovary
Conditions
Keywords
Granulosa Cell Tumour
Brief summary
Our proposal is to conduct an open phase II clinical trial that allows us to explore the activity of ketoconazole, an inhibitor of the enzyme CYP17, in ovarian granulosa tumors similar to what has been done in prostate cancer. The rational is based on dysregulation that FOXL2 mutations present in almost all granulosa tumors result in the expression of CYP17 that appears to be key in the development and progression of the disease. This work would represent the first attempt to address the treatment of ovarian granulosa cancer with a molecular solid rational, drawing on the recent identification of the mutation leader of this tumor. If succeed provide a widely available therapeutic alternative compared with current cancer therapies, with low toxicity. In addition it would open a new line of research with CYP17 enzyme inhibitors that could alter the course and outcome, usually fatal, in advanced stages of disease.
Interventions
DRUGKetoconazole
Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
Sponsors
Grupo Español de Tumores Huérfanos e Infrecuentes
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients obtained their written informed consent. * Women ≥18 years old. * ECOG ≤ 1. * Histologically confirmed carcinoma of granulosa cell in ovary. * Availability of sufficient biopsy material to confirm the diagnosis by a centralized pathologist and determination of the FOXL2 402C mutation → G (C134W). * Metastatic or unresectable disease. * Imaging measurable disease. * Life expectancy ≥ 12 weeks. * Patients with adequate hepatic function, defined by: * Serum values of AST and ALT ≤ 3 x UNL (except in the presence of metastases then allowed values ≤ 5 x UNL) * Total bilirubin ≤ 1.5 x UNL * Patients with adequate bone marrow function, defined by: * Absolute neutrophil count ≥ 1.5 x 10\*9 / L * Platelets ≥ 100 x 10\*9 / L * Hb \> 9 g / dL * Patients with adequate renal function: serum creatinine ≤ 1.5 x UNL. * Absence of any impediment to comply with the study protocol. * Women of childbearing potential, sexually active, not under hysterectomy or bilateral adnexectomy, should follow the following guidelines on contraception: * Negative serum or urine pregnancy test within 72 hours before the start of treatment. * Use of a medically accepted contraceptive method during: the 2 months prior to study treatment, during the study and 3 months after the last dose of study treatment.
Exclusion criteria
* Patients with another primary tumor 2 years before starting the study drug, with the exception of cervical carcinoma in situ or adequately treated or removed completely or basalioma or superficial bladder carcinoma. * Patients received radical radiotherapy ≤ 4 weeks before starting the study treatment or who have not recovered from the toxicities of radiotherapy. Palliative radiotherapy of painful bone lesions is allowed up to 14 days before the start of study treatment. * Patients with heart failure or clinically significant heart disease, including any of the following: * History or presence of uncontrolled severe ventricular arrhythmia. * Clinically significant bradycardia at rest. * LVEF \<45% assessed by 2-D echocardiogram (ECHO) or MUGA. * Any of the following diseases within 6 months prior to the start of study drug: Myocardial infarction (MI), severe or unstable angina, coronary revascularization, congestive heart failure (CHF), stroke (CVA), transient ischemic attack (TIA). * Patients with gastrointestinal function failure or gastric disease that significantly alter the ketoconazole absorption, for example, severe ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption, extensive resection (\> 1m) of the small intestine or inability to swallow oral medication. The partial or total gastrectomy is not an
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate | Every 8 weeks | The primary endpoint is overall response rate, defined as the proportion of patients with response defined as complete or partial response according to RECIST CRITERIA 1.1 measured by an external evaluator |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical benefit | Every 8 weeks | Clinical benefit defined as stable disease for more than 6 months plus complete and partial response rates, measured by an external evaluator. |
| Progression-free survival | Every 8 weeks | Progression-free survival is defined as the time since the start of treatment until progressive disease assessed (through evaluation by an external radiologist) according to RECIST 1.1, or death by any cause. |
| Overall survival | Untill death | Overall survival, defined as the time since the start of treatment until the patient dies by any cause. |
| Quality of life | Every 4 weeks | Quality of life measured by the validated in Spanish EORTC QLQ-C30 questionnaire. |
| Safety profile | Every 4 weeks | Toxicities will be classified according to the NCI-CTCAE v4.03 |
Countries
Spain
Outcome results
None listed